LENZ Therapeutics Announces FDA Approval of VIZZ for Treatment of Presbyopia
Published on August 1, 2025
SAN DIEGO—LENZ Therapeutics, Inc. (Nasdaq: LENZ) announced yesterday that the company has received U.S. Food and Drug Administration (FDA) approval for VIZZ (aceclidine ophthalmic solution) 1.44%. With this step, the solution becomes the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults. Samples are expected to be available in the United States as early as October 2025, the company stated, with commercial products to be broadly available by the middle of the fourth quarter this year. Direct-to-eyecare professional sales and marketing activities will be initiated immediately, the company advised.